Amgen (AMGN) fails to win panel backing for expanded Xgeva cancer use -Bloomberg
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Join SI Premium – FREE
Amgen (Nasdaq: AMGN) fails to win panel backing for expanded Xgeva cancer use -Bloomberg
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FTC files amicus brief challenging Amgen's Enbrel patent acquisition
- enVVeno Medical (NVNO) files $100M mixed shelf
- Kimbell Royalty closes $221.2M mineral rights acquisition
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
